| Literature DB >> 35118423 |
Lucile Vanhersecke1,2, Maxime Brunet2,3, Jean-Philippe Guégan4, Christophe Rey4, Antoine Bougouin5, Sophie Cousin3, Sylvestre Le Moulec6, Benjamin Besse7, Yohann Loriot7, Mathieu Larroquette2,3, Isabelle Soubeyran1, Maud Toulmonde3, Guilhem Roubaud3, Simon Pernot3, Mathilde Cabart3, François Chomy3, Corentin Lefevre3, Kevin Bourcier3, Michèle Kind8, Ilenia Giglioli5, Catherine Sautès-Fridman5, Valérie Velasco1, Félicie Courgeon4, Ezoglin Oflazoglu9, Ariel Savina9, Aurélien Marabelle7, Jean-Charles Soria7, Carine Bellera10, Casimir Sofeu10, Alban Bessede4, Wolf H Fridman5, François Le Loarer1,2, Antoine Italiano2,3,7.
Abstract
Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types. Here, using a large-scale retrospective analysis of three independent cohorts of cancer patients treated with anti-PD1/PD-L1 antibodies, we showed that the presence of mature TLS was associated with improved objective response rate, progression-free survival, and overall survival independently of PD-L1 expression status and CD8+ T-cell density. These results pave the way for using TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.Entities:
Keywords: Immune checkpoint inhibitors; biomarkers; tertiary lymphoid structures (TLS); tumor microenvironment
Mesh：
Substances：
Year: 2021 PMID： 35118423 PMCID： PMC8809887 DOI： 10.1038/s43018-021-00232-6
Source DB: PubMed Journal: Nat Cancer ISSN： 2662-1347